Overview Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) Status: Recruiting Trial end date: 2023-05-01 Target enrollment: Participant gender: Summary This study is a multi-center, open-label study of intravenous (IV) ANX005 in subjects with Amyotrophic Lateral Sclerosis ((ALS). Phase: Phase 2 Details Lead Sponsor: Annexon, Inc.Collaborator: Worldwide Clinical Trials